171 related articles for article (PubMed ID: 38193082)
1. Optimizing the cryopreservation and post-thaw recovery of natural killer cells is critical for the success of off-the-shelf platforms.
Saultz JN; Otegbeye F
Front Immunol; 2023; 14():1304689. PubMed ID: 38193082
[TBL] [Abstract][Full Text] [Related]
2. Cryopreservation has no effect on function of natural killer cells differentiated in vitro from umbilical cord blood CD34(+) cells.
Domogala A; Madrigal JA; Saudemont A
Cytotherapy; 2016 Jun; 18(6):754-9. PubMed ID: 27090754
[TBL] [Abstract][Full Text] [Related]
3. Cryopreserved PM21-Particle-Expanded Natural Killer Cells Maintain Cytotoxicity and Effector Functions
Oyer JL; Croom-Perez TJ; Dieffenthaller TA; Robles-Carillo LD; Gitto SB; Altomare DA; Copik AJ
Front Immunol; 2022; 13():861681. PubMed ID: 35464440
[TBL] [Abstract][Full Text] [Related]
4. Analysis of ex vivo expanded and activated clinical-grade human NK cells after cryopreservation.
Damodharan SN; Walker KL; Forsberg MH; McDowell KA; Bouchlaka MN; Drier DA; Sondel PM; DeSantes KB; Capitini CM
Cytotherapy; 2020 Aug; 22(8):450-457. PubMed ID: 32536506
[TBL] [Abstract][Full Text] [Related]
5. Ex vivo expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells through different receptor-ligand interactions.
Jung D; Baek YS; Lee IJ; Kim KY; Jang H; Hwang S; Jung J; Moon YW; Park KS; Choi YS; An HJ
J Exp Clin Cancer Res; 2021 Oct; 40(1):333. PubMed ID: 34686187
[TBL] [Abstract][Full Text] [Related]
6. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
7. Comparable transforming growth factor beta-mediated immune suppression in ex vivo-expanded natural killer cells from cord blood and peripheral blood: implications for adoptive immunotherapy.
Chaudhry K; Dowlati E; Long MD; Geiger A; Lang H; Gomez EC; Muniraj N; Sanchez CE; Singh PK; Liu S; Bollard CM; Cruz CRY
Cytotherapy; 2022 Aug; 24(8):802-817. PubMed ID: 35589475
[TBL] [Abstract][Full Text] [Related]
8. Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer.
Kennedy PR; Felices M; Miller JS
Stem Cell Res Ther; 2022 Apr; 13(1):165. PubMed ID: 35414042
[TBL] [Abstract][Full Text] [Related]
9. Human Natural Killer Cells Cryopreserved without DMSO Sustain Robust Effector Responses.
Das S; Niemeyer E; Leung ZA; Fritsch T; Matosevic S
Mol Pharm; 2024 Feb; 21(2):651-660. PubMed ID: 38230666
[TBL] [Abstract][Full Text] [Related]
10. Ex Vivo Expansion and CRISPR-Cas9 Genome Editing of Primary Human Natural Killer Cells.
Huang RS; Lai MC; Lin S
Curr Protoc; 2021 Sep; 1(9):e246. PubMed ID: 34529358
[TBL] [Abstract][Full Text] [Related]
11. Preservation of cell-based immunotherapies for clinical trials.
Li R; Johnson R; Yu G; McKenna DH; Hubel A
Cytotherapy; 2019 Sep; 21(9):943-957. PubMed ID: 31416704
[TBL] [Abstract][Full Text] [Related]
12. Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process.
Spanholtz J; Preijers F; Tordoir M; Trilsbeek C; Paardekooper J; de Witte T; Schaap N; Dolstra H
PLoS One; 2011; 6(6):e20740. PubMed ID: 21698239
[TBL] [Abstract][Full Text] [Related]
13. Successful expansion and cryopreservation of human natural killer cell line NK-92 for clinical manufacturing.
Lee S; Joo Y; Lee EJ; Byeon Y; Kim JH; Pyo KH; Kim YS; Lim SM; Kilbride P; Iyer RK; Li M; French MC; Lee JY; Kang J; Byun H; Cho BC
PLoS One; 2024; 19(2):e0294857. PubMed ID: 38394177
[TBL] [Abstract][Full Text] [Related]
14. Off-the-Shelf Prostate Stem Cell Antigen-Directed Chimeric Antigen Receptor Natural Killer Cell Therapy to Treat Pancreatic Cancer.
Teng KY; Mansour AG; Zhu Z; Li Z; Tian L; Ma S; Xu B; Lu T; Chen H; Hou D; Zhang J; Priceman SJ; Caligiuri MA; Yu J
Gastroenterology; 2022 Apr; 162(4):1319-1333. PubMed ID: 34999097
[TBL] [Abstract][Full Text] [Related]
15. Ex Vivo-expanded Natural Killer Cells Derived From Long-term Cryopreserved Cord Blood are Cytotoxic Against Primary Breast Cancer Cells.
Nham T; Poznanski SM; Fan IY; Vahedi F; Shenouda MM; Lee AJ; Chew MV; Hogg RT; Lee DA; Ashkar AA
J Immunother; 2018; 41(2):64-72. PubMed ID: 29189387
[TBL] [Abstract][Full Text] [Related]
16. Natural killer-92 cells maintain cytotoxic activity after long-term cryopreservation in novel DMSO-free media.
Pasley S; Zylberberg C; Matosevic S
Immunol Lett; 2017 Dec; 192():35-41. PubMed ID: 28966059
[TBL] [Abstract][Full Text] [Related]
17. Engineering the TGFβ Receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma.
Burga RA; Yvon E; Chorvinsky E; Fernandes R; Cruz CRY; Bollard CM
Clin Cancer Res; 2019 Jul; 25(14):4400-4412. PubMed ID: 31010834
[TBL] [Abstract][Full Text] [Related]
18. HLA Class I Knockout Converts Allogeneic Primary NK Cells Into Suitable Effectors for "Off-the-Shelf" Immunotherapy.
Hoerster K; Uhrberg M; Wiek C; Horn PA; Hanenberg H; Heinrichs S
Front Immunol; 2020; 11():586168. PubMed ID: 33584651
[TBL] [Abstract][Full Text] [Related]
19. Variable resistance to freezing and thawing of CD34-positive stem cells and lymphocyte subpopulations in leukapheresis products.
Berens C; Heine A; Müller J; Held SA; Mayer K; Brossart P; Oldenburg J; Pötzsch B; Wolf D; Rühl H
Cytotherapy; 2016 Oct; 18(10):1325-31. PubMed ID: 27491794
[TBL] [Abstract][Full Text] [Related]
20. Real-Time Tracking of
Uong TNT; Lee KH; Ahn SJ; Kim KW; Min JJ; Hyun H; Yoon MS
Front Immunol; 2018; 9():825. PubMed ID: 29770131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
